LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will ...
LOS ANGELES, May 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). The Board of Directors of Enochian BioSciences Inc. met today and expressed unanimous and strong affirmation of the current position of ...
LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today ...
OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Enochian Biosciences, Inc. plunged 36% on May 25, 2022 after its co-founder and largest shareholder, Dr. Serhat Gumrukçu, was arrested and charged by the ...
Enochian Biosciences Inc (NASDAQ:ENOB) shares are trading lower Wednesday after Hindenburg Research issued a bearish report on the company. Hindenburg noted that Gumrukcu is not only the co-founder of ...
Enochian Biosciences is a pre-clinical stage biotech that purchased its HIV drug IP from Weird Science, LLC. ENOB's lead scientist and HIV IP inventor does not appear to have any biotech experience, ...
Next Steps: If you acquired shares of Enochian Biosciences Inc. between September 24, 2020 and May 31, 2022, you have until September 26, 2022, to ask the court to appoint you lead plaintiff for the ...
LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today ...
Electronic trading platform E-Trade has reportedly blocked customers from buying Enochian Biosciences stock after the biotech announced the Food and Drug Administration had accepted its Pre-IND ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback